Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing.
This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step
in the expansion of its global network, the press release reads.
Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in
clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients.
Dr. Ursula Bausch, founder and CEO of Baccinex, said: “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.”
Dr. Andreas Raabe, founder and CEO of Adragos Pharma, said: “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”
Dr. Bausch will continue to lead Baccinex as CEO and will also remain a shareholder in the company.